Abstract
Background KS is a disease of multifocal vascular proliferation that requires infection with the KS herpes virus (KSHV/ HHV-8). Activation of the c-kit and platelet derived growth factor (PDGF) receptors by autocrine and paracrine mechanisms follows KSHV infection of endothelial cells. Partial KS regression in 5/10 patients was observed in a pilot study using the c-kit/PDGF-R inhibitor imatinib (Novartis Pharmaceuticals), and 3/4 biopsies showed PDGF inhibition, suggesting this agent has activity in AIDS-related KS.
Highlights
Kaposi’s sarcoma (KS) is a disease of multifocal vascular proliferation that requires infection with the KS herpes virus (KSHV/ HHV-8)
Partial KS regression in 5/10 patients was observed in a pilot study using the c-kit/platelet derived growth factor (PDGF)-R inhibitor imatinib (Novartis Pharmaceuticals), and 3/4 biopsies showed PDGF inhibition, suggesting this agent has activity in AIDS-related KS
Plasma concentrations of CCL5 (RANTES), IFNg, IL-6, and FGF-b at baseline, day 8, and day 28 were measured using the Mesoscale platform to assess the utility of these growth factors as biomarkers
Summary
KS is a disease of multifocal vascular proliferation that requires infection with the KS herpes virus (KSHV/ HHV-8). Activation of the c-kit and platelet derived growth factor (PDGF) receptors by autocrine and paracrine mechanisms follows KSHV infection of endothelial cells. Partial KS regression in 5/10 patients was observed in a pilot study using the c-kit/PDGF-R inhibitor imatinib (Novartis Pharmaceuticals), and 3/4 biopsies showed PDGF inhibition, suggesting this agent has activity in AIDS-related KS
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
